What was recalled
This page synthesizes the K1 / K2 / K3 source-form framework around vitamin K in commercial pet food. Vitamin K is the cofactor for the vitamin-K-dependent gamma-glutamyl carboxylase enzyme, which converts specific glutamic acid (Glu) residues on target proteins into gamma-carboxyglutamic acid (Gla) residues. The Gla modification is what makes prothrombin and the clotting cascade factors functional, what calcifies osteocalcin during bone mineralization, and what enables matrix Gla protein to inhibit pathologic vascular calcification. Without adequate vitamin K activity, these proteins are produced as inactive precursors (Glu-form osteocalcin, ucMGP) and the downstream physiology fails.
The three structural families of vitamin K are K1 phylloquinone (one phytyl side chain, found in leafy green vegetables and chlorophyll-containing plant tissues), K2 menaquinones (variable isoprenoid side chains numbered MK-4 through MK-13 — bacterial synthesis in fermented foods and gut microbiota, plus MK-4 from in-vivo conversion of K1 in some tissues), and K3 menadione (synthetic, no side chain — a precursor that the body alkylates to MK-4 after intestinal absorption). The three families share Gla-modification cofactor function but differ substantially in pharmacokinetics. K1 phylloquinone has approximately 1-2 hour serum half-life and is preferentially distributed to liver for clotting-factor carboxylation. MK-4 menaquinone has approximately 1 hour serum half-life but is preferentially distributed to extrahepatic tissues including brain, pancreas, and vascular endothelium. MK-7 menaquinone has approximately 3 day serum half-life and produces substantially higher and longer steady-state extrahepatic tissue concentrations than MK-4 or K1 from equivalent oral dose.
Commercial pet food vitamin K supplementation overwhelmingly relies on menadione sodium bisulfite complex, menadione dimethylpyrimidinol bisulfite, or menadione nicotinamide bisulfite — three K3 menadione complexes with improved shelf stability compared to free menadione. The body alkylates absorbed menadione to MK-4 menaquinone in target tissues. The conversion is metabolically active but produces predominantly MK-4 distribution, not MK-7. Direct K1 phylloquinone supplementation appears in some boutique and fresh-food formulations. Direct K2 menaquinone supplementation (particularly MK-7 from natto-derived fermentation) is essentially absent from the dry-kibble category despite establishing growing presence in human supplements and a small footprint in veterinary therapeutic diets.
Why it was recalled
The structural controversy has three layers. Layer one — AAFCO source-form agnosticism: AAFCO Nutrient Profiles specify minimum vitamin K activity per kg dry matter without distinguishing K1, K2, or K3 source forms. A diet meeting AAFCO minimum through menadione sodium bisulfite complex delivers a different pharmacokinetic profile than one meeting the same minimum through K1 phylloquinone or MK-7 menaquinone. The regulatory minimum is therefore not equivalent to a clinical sufficiency floor when the desired physiologic outcome is extrahepatic Gla-protein activation (osteocalcin, matrix Gla protein) rather than hepatic clotting-factor activation. The vitamin K1 phylloquinone controversy page covers the K1-specific side of this same source-agnostic framework.
Layer two — endogenous bacterial synthesis covers most healthy pets but not all: gut microbial synthesis of K2 menaquinones contributes substantially to total vitamin K status in healthy companion animals. Antibiotic-treated pets (particularly prolonged or broad-spectrum regimens), pets with chronic enteropathies disrupting microflora, sulfa-drug-treated rodents and rabbits, and pets on warfarin or warfarin-derivative anticoagulant rodenticide exposure are documented exceptions to the bacterial-synthesis adequacy assumption. The regulatory framework treats dietary K as a backstop rather than a primary delivery system because endogenous synthesis usually suffices, but the backstop role becomes load-bearing in specific clinical contexts that AAFCO labeling does not flag.
Layer three — bone and vasculature Gla-protein activation evidence is human-dominant: the modern interest in MK-7 supplementation derives from human observational and intervention studies linking higher MK-7 status with lower vascular calcification and improved bone mineral density. Companion-animal controlled-trial evidence for MK-4 or MK-7 supplementation effect on bone or vasculature is essentially absent. The pharmacokinetic distinction is established (MK-7 produces higher and longer extrahepatic tissue exposure than MK-4 or K1 from equivalent dose), but translating that distinction into pet-specific clinical recommendation requires data that has not been generated. The pet food category therefore remains conservative on K2 supplementation despite the mechanistic plausibility for senior orthopedic and renovascular support.
Health risks for your pet
Dietary vitamin K deficiency in commercial-fed dogs and cats is uncommon at the population level because of endogenous bacterial synthesis plus dietary AAFCO compliance through menadione supplementation. Acute deficiency presents primarily through coagulopathy — prolonged prothrombin time, prolonged activated partial thromboplastin time, ecchymoses, mucosal bleeding, hematuria, and in severe cases life-threatening internal hemorrhage. The classic non-dietary etiology is warfarin or warfarin-derivative anticoagulant rodenticide ingestion, where the K-dependent gamma-glutamyl carboxylase reductive recycling pathway is inhibited and the body cannot regenerate active vitamin K from its oxidized form. Veterinary treatment is parenteral and oral phylloquinone (K1) administration for 14-30 days depending on rodenticide half-life; menadione is less effective for this indication because of the metabolic activation requirement.
Subclinical inadequacy of extrahepatic Gla-protein activation is a more theoretical concern grounded in human cardiovascular and orthopedic supplementation literature. Hepatic clotting-factor carboxylation has higher priority than extrahepatic osteocalcin and matrix Gla protein carboxylation when total vitamin K availability is limited; an animal can have adequate clotting-factor activity (normal PT, normal aPTT) while still having suboptimal osteocalcin and matrix Gla protein carboxylation. The clinical significance of this subclinical extrahepatic insufficiency in companion animals is unclear in the absence of dedicated controlled-trial evidence. Direct K2 menaquinone (particularly MK-7) supplementation would address this theoretical gap with greater confidence than menadione-derived MK-4, but the practice is essentially absent from the dry-kibble category.
What to do if you bought affected product
Pet owners can manage vitamin K adequacy through several practical approaches: (1) most healthy pets on AAFCO-compliant commercial diets do not require additional vitamin K supplementation — the combination of dietary supplementation (typically menadione) plus endogenous bacterial synthesis covers requirements adequately for clotting-factor activity; (2) antibiotic-treated pets on prolonged or broad-spectrum regimens can benefit from veterinary monitoring of clotting times and short-course phylloquinone supplementation if PT prolongation is documented; (3) warfarin or anticoagulant rodenticide exposure is a veterinary emergency requiring parenteral and oral phylloquinone (K1, not menadione K3) for 14-30 days under professional supervision; (4) senior pets with orthopedic concerns or chronic kidney disease may benefit from veterinary discussion of K2 menaquinone supplementation (typically MK-4 or MK-7 as targeted nutraceutical) given the theoretical extrahepatic Gla-protein activation rationale, though companion-animal trial evidence is limited; (5) request K source-form disclosure from brand customer service — brands using menadione sodium bisulfite complex will usually disclose on direct inquiry; brands using K1 phylloquinone or K2 menaquinone are less common but typically promote the distinction; (6) avoid double-supplementation — pets on AAFCO-compliant diets typically do not need additional dietary vitamin K, and stacked multivitamin or kelp-based supplementation can produce variable total K activity intake without clear benefit.
How this affects KibbleIQ’s grade
The KibbleIQ rubric v15 does not currently differentiate vitamin K source form per our published methodology, since brand-level disclosure of K1 / K2 / K3 source form is rare and the extrahepatic Gla-protein activation framework is not yet supported by companion-animal controlled-trial evidence. Future rubric extension under consideration: brands publishing vitamin K source-form disclosure (particularly K1 phylloquinone or direct K2 menaquinone inclusion above standard menadione) would receive favorable scoring weight, with weighting calibrated to evidence base as it develops. For now, our recommendation: assume AAFCO-compliant commercial diets meet clotting-factor requirements adequately for healthy pets; reserve direct K2 supplementation discussion for senior orthopedic or chronic kidney disease contexts under veterinary guidance; and treat the K1 / K2 / K3 source-form question as an active inquiry to brand customer service rather than as a label-derivable signal.